Takeda Pharmaceutical Company Limited American Depositary Shares (each (NY:TAK)

17.86 UNCHANGED

Official Closing Price Updated: 7:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Takeda Pharmaceutical Company Limited American Depositary Shares (each

< Previous 1 2

...

14 15 16 17 18 19 20 21 Next >

Alofisel®▼ (darvadstrocel) Shows Clinical Remission Rate at Six-Months in the Real-World INSPIRE Study Interim Analysis Consistent with the Pivotal Clinical ADMIRE-CD Study1,2

February 18, 2022

From Takeda Pharmaceutical Company Limited

Via Business Wire

The Best Russell 2000 Stocks to Buy Before they Rebound ↗

February 15, 2022

Some of the best stocks in the market are among the best Russell 2000 stocks to buy. Here's a list of a few of those choices.

Via InvestorPlace

Why Are Seagen Shares Sinking Today? ↗

February 10, 2022

Seagen Inc (NASDAQ: SGEN) reported Q4 revenues

Via Benzinga

Take a Leap Into Novavax Stock After Vaccine Sales Start ↗

February 08, 2022

Novavax is worth speculating on at current levels. NVAX stock has fallen below the $100 mark ahead of its global Covid-19 vaccine launch.

Via InvestorPlace

FDA Approves Takeda's Vonvendi As Prophylactic Treatment In Bleeding Disorder ↗

January 31, 2022

The

Via Benzinga

A News Blizzard ↗

February 04, 2022

Markets are still down despite very encouraging news in January when 467,00 new hires got jobs.

Via Talk Markets

Takeda Delivers Strong Third Quarter FY2021 Results and Raises Full-Year Forecast Reflecting Strong Momentum

February 03, 2022

From Takeda Pharmaceutical Company Limited

Via Business Wire

FDA Approves Prophylactic Treatment with VONVENDI® [von Willebrand Factor (Recombinant)] for Adult Patients Living with Severe Type 3 von Willebrand Disease (VWD)

January 31, 2022

From Takeda Pharmaceutical Company Limited

Via Business Wire

Worldwide Adoption of Novavax Vaccines Makes It a Winner ↗

January 21, 2022

Novavax can still generate billions of dollars of revenue per year from its shot, making NVAX stock quite attractive at its current levels.

Via InvestorPlace

Takeda Named Global Top Employer for Fifth Consecutive Year

January 19, 2022

From Takeda Pharmaceutical Company Limited

Via Business Wire

More Serious Matters ↗

January 14, 2022

Wall Street fell on new worries about inflation and a drop in retail sales levels.

Via Talk Markets

Denali Stock Tumbles; Why Biogen Isn't The Only Alzheimer's Play Under Pressure ↗

January 13, 2022

Denali Therapeutics is under pressure after the FDA put its study on hold.

Via Investor's Business Daily

Interest Rate Hikes And Stocks ↗

January 12, 2022

Abnormal flooding in northwest Brazil has blocked iron ore mining which resulted in a jump in the price of ore.

Via Talk Markets

Takeda Emphasizes Strategy for Delivering Sustainable Growth Over Next Decade at the 40th Annual J.P. Morgan Healthcare Conference

January 10, 2022

From Takeda Pharmaceutical Company Limited

Via Business Wire

Takeda to Acquire Adaptate Biotherapeutics to Develop Novel Gamma Delta (γδ) T Cell Engager Therapies Targeting Solid Tumors

January 10, 2022

From Takeda Pharmaceutical Company Limited

Via Business Wire

Post-Fed Thursday ↗

January 06, 2022

Companies earning in dollars but incorporated abroad and paying dividends in other currencies were big gainers today.

Via Talk Markets

FDA Rejects Takeda's Eosinophilic Esophagitis Candidate, Asks For Additional Study ↗

December 22, 2021

Takeda Pharmaceutical Co Ltd (NYSE: TAK) received a Complete Response Letter (CRL) from the FDA for its marketing application for TAK-721 (budesonide oral...

Via Benzinga

The Daily Biotech Pulse: Allakos Slips Negative Late-Stage Data, Pfizer & Merck Announce Fresh COVID Pill Deal With UK, Regulatory Setback For Takeda ↗

December 22, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Allakos's Lirentelimab Flunks Late-Stage Studies In Patients With...

Via Benzinga

Takeda Receives Complete Response Letter from the U.S. FDA for TAK-721

December 21, 2021

From Takeda Pharmaceutical Company Limited

Via Business Wire

Systemic Mastocytosis Treatments Gain Hope Due To Increasing Novel Treatment Options

December 21, 2021

Palm Beach, FL –December 21, 2021 – FinancialNewsMedia.com News Commentary – Systemic mastocytosis is rare disease which affects very few people and it causes due to C-kit mutation which leads to...

Via FinancialNewsMedia

The Daily Biotech Pulse: Calliditas Snags FDA Nod, Novartis to Buy Back $15B In Shares, Valneva Touts Vaccine Data, Immix, Bionomics Debut On Wall Street ↗

December 16, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Calliditas Gets Conditional Approval For Kidney Inflammation Disease Drug...

Via Benzinga

Novavax Files For Approval Of Its COVID-19 Vaccine In Japan ↗

December 16, 2021

Novavax Inc (NASDAQ: NVAX) has submitted a marketing application in Japan seeking approval for its COVID-19 vaccine by its partner Takeda Pharmaceutical Co Ltd...

Via Benzinga

3 Stocks That Can Make You Rich in Just a Few Years ↗

December 14, 2021

Investing in the most popular stocks on the Street won't make investors rich in a few years. To accomplish that goal, a contrarian spirit is needed.

Via InvestorPlace

Comparing Data: Sanofi Vs. Johnson & Johnson Multiple Myeloma Therapies In Newly Diagnosed Patients ↗

December 13, 2021

Sanofi SA (NASDAQ: SNY) and Johnson & Johnson (NYSE: JNJ) posted new data from their myeloma therapies, Sarclisa and Darzalex, respectively. Data were shared at...

Via Benzinga

Takeda Drives Continued Scientific Leadership Through Real-World Evidence in Rare Hematological Diseases at ASH 2021

December 13, 2021

From Takeda Pharmaceutical Company Limited

Via Business Wire

Takeda Announces Publication of Data from SOLSTICE, a Pivotal Phase 3 Trial for LIVTENCITY™ (Maribavir) in Post-Transplant Recipients With Cytomegalovirus (CMV) Infection (Refractory, With or Without Resistance)

December 08, 2021

From Takeda Pharmaceutical Company Limited

Via Business Wire

7 Best Drug Stocks to Buy for 2022 Without Covid Catalysts ↗

December 07, 2021

These seven drug stocks, a mix of growth, value, and moonshot plays, each stand to see big moves in the next twelve months.

Via InvestorPlace

Takeda Unveils New Research to Advance Patient Care in Hematology and Oncology at 63rd American Society of Hematology (ASH) Annual Meeting

December 07, 2021

From Takeda Pharmaceutical Company Limited

Via Business Wire

Takeda’s LIVTENCITY™ (maribavir) Now Available for Certain Individuals Ages 12 Years and Older With Post-Transplant Cytomegalovirus (CMV) Infection/Disease in the United States

December 02, 2021

From Takeda Pharmaceutical Company Limited

Via Business Wire

Happy December ↗

December 01, 2021

Inflation levels this year will almost certainly lower growth in 2022 because of inflation this year in everything from house prices....to stock prices.

Via Talk Markets

< Previous 1 2

...

14 15 16 17 18 19 20 21 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.